Key result
Arsenic therapy for acute promyelocytic myeloid leukemia carries a potential risk of QT prolongation.
Why the study?
In patients with acute promyelocytic myeloid leukemia receiving arsenic therapy, a main concern is the potential for QT prolongation.
Does arsenic therapy cause QT prolongation in patients with acute promyelocytic myeloid leukemia?
Does arsenic therapy cause QT prolongation in patients with acute promyelocytic myeloid leukemia?
Arsenic therapy for acute promyelocytic myeloid leukemia carries a known risk of QT prolongation.
Answers are grounded in this paper and cite their sources.
May warrant QTc monitoring during arsenic therapy for APL; leaves open precise incidence and predictors from Level 5 data.
For patients with acute promyelocytic myeloid leukemia (APML), arsenic therapy remains a primary therapy. A main concern with arsenic therapy is the potential for prolongation of the QT, which can ...
No takes yet. Share an insight, caveat, or question.
Zacharias et al. (2025) studied this question. Arsenic therapy for acute promyelocytic myeloid leukemia carries a potential risk of QT prolongation.
Synapse has enriched 10 related papers. Consider them for comparative context: